<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220824055790N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-09-13</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of  Ketamin/Propofol (Ketofol) and  Etomidate /Fentanyl (Etofen) in reduction of shoulder dislocation</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of  Ketamin/Propofol (Ketofol) and  Etomidate /Fentanyl (Etofen) combinations for procedural sedation and analgesia  of anterior shoulder dislocation reduction in Emergency Department: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>46</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65534</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients will be randomly assigned to one of the Ketofol or Etofen groups. Randomization is done using a table of random numbers and by the block randomization method and in blocks of 5 people. In this way, a number is blindly selected from the table of random numbers for each position, and the two digits on the right side of it, if they are between 1 and 46, will be assigned to that position.
Each of the blocks of 5 people is assigned to one group (Ketofol or Etofen).  The odd blocks belong to the Ketofol group and the even blocks belong to the Etofen group. Block positions are numbered (1 to 46). For example, the first case that is randomly assigned to Ketofol group will enter the number one position of the first block (the block related to Ketofol) and this process will be done until the positions are filled and the number of samples in the two groups will be equal. , Blinding description: Ketamin and Fentanyl drugs are colorless and have no difference in color, and the patient does not know which compound is being injected.
Propofol is milky. Etomidate is available in two milky and colorless forms. A milky etomidate is used for the study to be similar to Propofol.
Therefore, in each of the study groups, a colorless compound + a milky compound is used, and the patient is unaware of the type of drug.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Anterior Shoulder Dislocation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: According to the PSAs protocol, Ketofol with a dose of 0.75 mg/kg IV bolus of ketamine and propofol are given as starting doses. A repeat dose of 0.375 mg/kg ketamine and propofol every 3 minutes is given until adequate sedation is achieved. The goal of sedation in this study is to reach the patient's level of moderate sedation. The patient is apparently unconscious, but reacts with skin irritation. After the patient reaches the appropriate level of sedation, the emergency physician performs the sedation using the Liddle Meyer maneuver. And in case of failure, the same maneuver is repeated once more, and if it is still not successful, the next maneuver is traction. After successful reduction, the pain score, the number of reduction attempts, and the length of stay in the emergency room are measured. Intervention 2: Intervention group: According to the PSAs protocol, Etofen with a dose of 0.15 mg/kg IV bolus of etomidate and 0.15 µg/kg of fentanyl are given as starting doses. A repeat dose of 0.1 mg/kg etomidate every 2 minutes is given until adequate sedation is achieved. The goal of sedation in this study is to reach the patient's level of moderate sedation. The patient is apparently unconscious, but reacts with skin irritation. After the patient reaches the appropriate level of sedation, the emergency physician performs the sedation using the Liddle Meyer maneuver. And in case of failure, the same maneuver is repeated once more, and if it is still not successful, the next maneuver is traction. After successful reduction, the pain score, the number of reduction attempts, and the length of stay in the emergency room are measured.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Measured variables are available after unidentifiable individuals.

When:
Up to one year after publish results.

To whom:
All people in the research centers.

Conditions:
Allowed for any use.

Where to obtain:
Seyed Mojtaba Habibi Khorasani
mojista.1375@gmail.com

How to obtain:
After contacting and knowing the identity of the person, information will be provided to them.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Mojtaba Habibi Khorasani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Bahonar Hospital</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7613747181</zip>
        <telephone>+98 34 3223 5011</telephone>
        <email>mojista.1375@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Masoumeh Nazemi Rafei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Bahonar Hospital</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7613747181</zip>
        <telephone>+98 34 3223 5011</telephone>
        <email>m_nazemi_r@yahoo.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Adults between 18 and 50 years old
Anterior shoulder dislocation</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of allergy to any of the drugs (ketamine, propofol, etomidate, fentanyl)
underlying cardiovascular disease
lung diseases
nervous system diseases (central or peripheral)
history of current drug or stimulant abuse now or in the last month
associated fracture
neurovascular symptoms
patient dissatisfaction
associated diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S43.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Subluxation and dislocation of shoulder joint</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: According to the PSAs protocol, Ketofol with a dose of 0.75 mg/kg IV bolus of ketamine and propofol are given as starting doses. A repeat dose of 0.375 mg/kg ketamine and propofol every 3 minutes is given until adequate sedation is achieved. The goal of sedation in this study is to reach the patient's level of moderate sedation. The patient is apparently unconscious, but reacts with skin irritation. After the patient reaches the appropriate level of sedation, the emergency physician performs the sedation using the Liddle Meyer maneuver. And in case of failure, the same maneuver is repeated once more, and if it is still not successful, the next maneuver is traction. After successful reduction, the pain score, the number of reduction attempts, and the length of stay in the emergency room are measured.</i_keyword>
      <i_keyword>Intervention group: According to the PSAs protocol, Etofen with a dose of 0.15 mg/kg IV bolus of etomidate and 0.15 µg/kg of fentanyl are given as starting doses. A repeat dose of 0.1 mg/kg etomidate every 2 minutes is given until adequate sedation is achieved. The goal of sedation in this study is to reach the patient's level of moderate sedation. The patient is apparently unconscious, but reacts with skin irritation. After the patient reaches the appropriate level of sedation, the emergency physician performs the sedation using the Liddle Meyer maneuver. And in case of failure, the same maneuver is repeated once more, and if it is still not successful, the next maneuver is traction. After successful reduction, the pain score, the number of reduction attempts, and the length of stay in the emergency room are measured.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score: using numerical rating scale. Timepoint: During Reduction. Method of measurement: Ask the patient: Score from 1 to 10.</prim_outcome>
      <prim_outcome>Number of reduction attempts until reduction succeeds. Timepoint: During study until reduction succeeds. Method of measurement: -.</prim_outcome>
      <prim_outcome>Length of stay in the emergency room: the time between the patient's admission to the emergency room and discharge. Timepoint: After discharge. Method of measurement: View the patient file.</prim_outcome>
      <prim_outcome>Drug side effects: bradycardia, respiratory depression, hypotension. Timepoint: During Study. Method of measurement: Based on the form of drug side effects.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-31</approval_date>
        <contact_name>Ethics commitee of Kerman Medical University</contact_name>
        <contact_address>University of Medical Sciences, The beginning of Haft Bagh Alavi axis, Kerman Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
